| Expression pattern: |
UP |
| Associated gene: |
MAPT / microtubule-associated protein tau |
| Associated microRNA: |
miR-1205 |
| Biological function: |
Promotes docetaxel resistance of prostate cancer cells, increases IC50 and colony formation, decreases apoptosis after docetaxel treatment, and transfers chemoresistance through resistant-cell-derived exosomes. |
| Molecular mechanism: |
Exosomal circSLC4A7 acts as a competing endogenous RNA that sponges miR-1205, thereby regulating MAPT and promoting docetaxel resistance in prostate cancer. |
| Biological pathway or process: |
ceRNA regulation (promotes); drug resistance (promotes); chemoresistance (promotes); apoptosis (inhibits); proliferation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Actinomycin D / DRB Stability Assay; RT-qPCR; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; TUNEL; Luciferase Reporter Assay; Western Blot; In Vivo Animal Model; H&E Staining; Bioinformatics Analysis |
| Clinical significance: |
May provide a new treatment strategy for docetaxel resistance of prostate cancer. |
| Description: |
circSLC4A7 is up-regulated in docetaxel-resistant prostate cancer cells and their exosomes. It promotes docetaxel resistance by sponging miR-1205 and regulating MAPT, resulting in increased cell viability/colony formation and reduced apoptosis under docetaxel treatment. Silencing circSLC4A7 reduces resistance in vitro and in a cell line-derived xenograft model. |
| Confidence score: |
0.6443 |